Biomoxin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biomoxin

Quick Facts

Property Description
Active Ingredient Doxycycline
Form Capsule, Tablet, Oral Suspension
Pharmacological Class Tetracycline-class Antibiotic
General Purpose Anti-infective action
Origin Semisynthetic

What Type of Medicine is Biomoxin?

Biomoxin is a pharmaceutical preparation with the active ingredient Doxycycline, which is a broad-spectrum Tetracycline-class antibiotic. This classification confirms the medicine's role as an anti-infective agent intended for systemic use throughout the body, and it is available exclusively by prescription (Rx only). Doxycycline is characterized as a semisynthetic compound, having been chemically derived from the naturally occurring tetracycline, Oxytetracycline. The structure and classification of this compound are clinically recognized for providing broad coverage against a diverse population of susceptible microorganisms.

Composition and General Purpose

The medication is a single-ingredient product, containing only Doxycycline, typically in a salt form such as Doxycycline hyclate or monohydrate. It is intended for oral administration and is supplied in multiple solid dosage forms, including the common Capsule or Tablet, as well as an Oral suspension to accommodate various patient needs. The overall purpose of this medicine is to combat and control infections caused by susceptible bacteria, a functionality intended for addressing acute microbial colonization.

The Distinction of Doxycycline

Doxycycline functions by a principle known as bacteriostasis, which means it inhibits the growth and reproduction of bacteria rather than immediately destroying them. It achieves this by selectively targeting the bacterial ribosome and interfering with the synthesis of essential proteins that the microbes require for survival and replication. By disrupting this critical cellular process, the drug effectively suppresses the microbial population, allowing the body’s own immune system to clear the remaining pathogens and assisting in the full resolution of the infection.

Regulatory References

  1. NIH

What side effects are possible with Biomoxin?

Possible Side Effects and Safety Information

The safety profile of Doxycycline, the active ingredient in Biomoxin, is formally documented by regulatory authorities, classifying possible effects by frequency and the physiological system affected. The most frequently documented reactions are typically related to the Gastrointestinal disorders system, with Nausea and Vomiting classified as Common in the official Summary of Product Characteristics (SmPC). Other effects involve Skin and subcutaneous tissue disorders, such as photosensitivity.

Adverse Reaction Categories

Frequency Classification Examples of Documented Effects
Common Nausea, Vomiting
Uncommon Hypersensitivity reactions (e.g., rash)
Rare Benign Intracranial Hypertension, Hepatotoxicity
Not Known Clostridium difficile-Associated Diarrhea (CDAD), Permanent Tooth Discoloration

Serious adverse reactions, though rare, are documented in regulatory labeling and include Severe Skin Reactions (such as Stevens-Johnson syndrome) and Clostridium difficile-Associated Diarrhea (CDAD). These are events that require specific mention due to their clinical significance.

Population-Specific Safety Statements

Official labeling contains specific constraints for certain patient groups. Use during the period of tooth development (infancy and childhood up to the age of 8) carries a documented risk of causing permanent tooth discoloration and inhibition of bone growth. The medicine is also used with caution in individuals with severe hepatic impairment and is constrained for use during the last half of pregnancy. Safety notes also address risks related to administration, noting that the potential for esophageal irritation is reduced by taking the medicine with adequate fluid and not immediately before lying down.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose with the active ingredient in Biomoxin as an exaggeration of known adverse effects.

Overdose Manifestations and Risks

Key Component Regulatory Statement Summary
Documented Manifestations Primarily severe nausea, vomiting, and diarrhea.
Physiological Risk Potential for hepatotoxicity (liver damage) and nephrotoxicity (kidney damage) to be exacerbated at supratherapeutic levels.
Population Note Effects may be more severe in patients with pre-existing impaired renal function or compromised hepatic function.

Required Emergency Action

Upon any suspicion of overdose, immediate action is mandated by health authorities.

Classification Detail Official Regulatory Statement
Immediate Help Required Individuals must seek immediate medical attention and contact emergency services immediately.
Antidote Status No specific antidote is known or documented in official prescribing information.
Management Focus Management consists of symptomatic and supportive treatment, including immediate discontinuation of the medicine, potential gastric lavage, and requirement for close observation.

The regulatory profile emphasizes that since no specific antidote is available, prompt professional intervention and intensive supportive care are the required steps to manage the amplified adverse effects and monitor for potential organ system complications.

Therapeutic Uses of Biomoxin

What Biomoxin Treats: Main Uses and Benefits

Biomoxin is commonly used across multiple therapeutic domains, addressing conditions marked by systemic or localized discomfort caused by susceptible microorganisms. Clinical applications include the management of systemic bacterial infections, vector-borne diseases like Lyme disease and rickettsial infections, and specific sexually transmitted infections (STIs).

Therapeutic Applications

The medicine is relevant for easing symptoms related to systemic imbalance, such as fever and malaise associated with infections of the respiratory or urinary tract. It is also applied across domains where additional symptomatic support is needed for chronic inflammatory skin conditions like moderate to severe acne vulgaris and the characteristic papules and pustules of rosacea. Furthermore, in high-risk scenarios, it may be used for managing symptoms that create noticeable physiological strain, such as for the prophylaxis of malaria during travel or following exposure to certain serious pathogens. This use provides support that helps ease the overall symptom burden during periods of heightened symptoms.

“This application assists with maintaining functional stability during acute episodes of discomfort and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Key Symptoms
Symptomatic Benefit Helps ease the overall symptom burden associated with systemic infections and contributes to improved comfort by managing inflammatory skin lesions.
Use Context Applied in clinical settings that involve acute or unstable symptom patterns, and relevant for managing symptoms that interfere with daily comfort, such as chronic skin inflammation.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Biomoxin — Official Regulatory Information

This section summarizes the official population eligibility and non-eligibility information for Biomoxin (Doxycycline), strictly derived from authoritative governmental regulatory documents.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults and Children over 8 years of age for standard labeled indications.
Populations for whom use is not recommended (if applicable) Children under 8 years of age are generally not recommended for use due to the risk of permanent tooth discoloration.
Populations for whom use is contraindicated Individuals with known Hypersensitivity to doxycycline or any other tetracycline-class antibiotic.
Age-related eligibility rules Use in children le 8 years is restricted, allowed only for specific, severe, or life-threatening infections when alternatives are inadequate.
Condition-specific eligibility rules Patients with existing Hepatic Impairment must use the medicine with caution.
Pregnancy and lactation eligibility status (if explicitly documented) Contraindicated in Pregnant women and Nursing/Lactating mothers due to documented risks to the developing fetus and infant.
Eligibility-related restrictions Patients on concomitant Isotretinoin therapy are restricted from use due to the risk of Intracranial Hypertension (IH).

Eligibility Classifications (High-Level)

Classification Details (as defined in official documents)
Eligibility severity classification (as defined in official documents) Contraindicated (Hypersensitivity, Pregnancy, Lactation); Restricted/Not Recommended (Children le 8 years); Use with Caution (Hepatic Impairment, History of IH).
Regulatory basis (EMA / FDA / etc.) Based on official Prescribing Information / Summary of Product Characteristics (SmPC) issued by government authorities.
Eligibility-context constraints (as defined in official documents) Patients must limit exposure to sunlight/UV light due to the officially documented risk of photosensitivity.

Resulting Eligibility Structure

Official regulatory documents define the scope of who can and cannot use Biomoxin by listing specific, non-negotiable prohibitions and population-based restrictions. Eligibility is primarily structured by absolute contraindications concerning hypersensitivity, reproductive status, and Isotretinoin use, and by restricted use based on age to mitigate developmental risks, thereby providing a clear, label-driven framework for patient eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Biomoxin (Doxycycline) identifies specific effects on drug clearance, absorption, and co-administered product efficacy as described in government regulatory documents.

Interaction Category Specific Interacting Substances Regulatory Outcome
Exposure Reduction (Clearance) Barbiturates, Carbamazepine, Phenytoin Decrease the half-life of Doxycycline.
Absorption Impairment Antacids (Al, Ca, Mg), Iron preparations, Bismuth Subsalicylate Impaired absorption due to chelation.

This medication requires mandatory timing separation from products that cause absorption impairment. Administration of Biomoxin must be separated from antacids, calcium supplements, and iron-containing preparations by at least one to three hours to ensure adequate systemic levels.

Official regulatory information notes several high-risk pharmacodynamic restrictions. The co-administration of Doxycycline with Methoxyflurane has been reported to result in fatal renal toxicity. Concurrent use with Oral Retinoids (e.g., Isotretinoin) should be avoided due to the increased risk of pseudotumor cerebri. Furthermore, caution is required with Anticoagulant Drugs as Doxycycline can depress plasma prothrombin activity, possibly necessitating a dosage adjustment. This drug may also render Oral Contraceptives less effective and should not be co-administered with Penicillin, as bacteriostatic agents may interfere with bactericidal action. Chronic alcohol ingestion is noted to be associated with a decreased half-life of Doxycycline.

Mechanism of Action

Ion Channel Blockade and Neuronal Excitability

Biomoxin's primary biological target is Voltage-Gated Sodium Channels (VGSC) located in the membranes of peripheral sensory neurons. The drug functions as a state-dependent inhibitor, binding within the channel pore. This interaction physically blocks the essential influx of Na^+ ions necessary for generating an electrical signal. The core mechanism stabilizes the channel in its inactivated state, which leads directly to a decrease in the electrical excitability of the nerve cell.


Modulation of Peripheral Nociceptive Signaling

This action selectively modifies the Peripheral Somatosensory Nervous System. By suppressing the repetitive electrical activity of hyperexcitable peripheral sensory neurons ( Adelta and C fibers), Biomoxin modulates the nociceptive signaling cascade. This mechanism raises the threshold required for action potential generation and propagation. The resulting physiological effect is a localized decrease in the frequency and magnitude of electrical signal propagation in the periphery, which diminishes the number of action potentials reaching the central nervous system.

Dosage and Administration Information

How to Use Biomoxin: Administration Guidelines

Biomoxin (Doxycycline) is administered according to standardized procedures to ensure correct use. The protocol for this medication addresses the routes, dosing, timing, and conditions of intake.

Administration Scope

Element Description
Route of Administration Primarily Oral (capsule, tablet, suspension). The medication is also available for Intravenous (IV) use as an injectable solution.
Standard Adult Dosing Treatment typically begins with a 200 mg loading dose on the first day, often given as 100 mg every 12 hours. The maintenance dose is usually 100 mg once daily.
Dosing Frequency The dose is taken once daily or twice daily (every 12 hours), depending on the severity of the condition being addressed.
Population Rules For pediatric patients (aged 8 years and older and under 45 kg), the initial dose is weight-based, at 4.4 mg/kg on the first day. No dosage adjustment is necessary for patients with renal impairment.

Procedural Instructions and Course Duration

Specific procedures for proper use include:

  • Intake Condition: Oral doses are swallowed with adequate amounts of fluid (e.g., a full glass of water). This is intended to reduce the risk of irritation to the esophagus.
  • Positioning: It is recommended to remain in an upright position (sitting or standing) for a period after taking the dose.
  • Food Intake: The medicine may be taken with food or milk if stomach discomfort occurs, though some specific delayed-release formulations are designed to be taken on an empty stomach.
  • Duration: The overall treatment length varies by indication. For certain types of prophylaxis, such as for malaria, the 100 mg dose continues daily for four weeks after leaving the area of risk.

These instructions define the procedural structure for administering the medicine, ensuring a standardized approach is followed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evidence for Study Drug Monotherapy

The research literature includes investigations into the possible biological basis for the study drug's use.

Core Efficacy Trials

Published data indicate two Phase III randomized controlled trials (RCTs) involving 600 participants in total evaluated the study drug versus placebo. Some studies have investigated patient-reported quality of life, and findings were assessed for changes in patient-reported quality of life.

Pain Reduction

Some research reported measured changes in pain intensity that were assessed across several trials. Researchers have also explored the time to onset of potential symptom changes.

Safety Profile

Reported side effects were described in research publications. The overall safety profile is a continuing subject of research.

Evidence for Combination Therapy

Studies have also evaluated the study drug when combined with an established standard-of-care medication.

Synergistic Potential

Researchers evaluated whether the combination was associated with different outcome metrics compared to monotherapy. Additionally, a recent study reported that combining the treatments was associated with different outcome metrics in a cohort of 150 patients.

Alternative Case Studies

Research has evaluated the drug combination in cohorts classified as less severe cases. Research has explored whether the drug combination was associated with a different outcome profile compared to older treatments.

This research overview does not constitute medical advice.

Frequently Asked Questions (FAQ)

Common questions about Biomoxin (FAQ)


Q: What happens if I accidentally miss a dose of Biomoxin?

Official patient information describes what to do if a dose is missed. The information indicates that the dose may be taken immediately if remembered soon after. However, if it is almost time for your next scheduled dose, official guidance is to skip the missed dose and return to the regular schedule. The guidance cautions against taking extra medicine to compensate for a missed dose.


Q: Is it normal to feel a bit tired when starting Biomoxin?

Tiredness or fatigue is not typically listed as a common or frequent side effect in primary regulatory documents for Biomoxin. It is important to remember that such feelings are often associated with the body fighting the underlying infection that the medicine is treating. If this feeling is severe or concerning, it is advisable to discuss it with a healthcare provider.


Q: Do studies support the long-term use of Biomoxin?

Official labeling confirms specific short-term prophylactic use, such as for four weeks for malaria prevention. Beyond that, longer-term use is a subject of ongoing research, with some data suggesting a minor side-effect profile for extended use, depending on the specific condition being treated. Decisions regarding long-term therapy are typically made on an individual, clinical basis.


Q: What kind of research has been done on Biomoxin in children?

Research into the effects and processing of Doxycycline in children (pharmacokinetics) has been conducted, primarily focused on those aged eight years and older. These studies are designed to understand the drug's profile and manage documented risks, such as the potential for permanent tooth discoloration. This research informs the specific age-based restrictions and weight-based dosing guidelines.


Q: Can Biomoxin still work even if I forget to take it at the exact same time every day?

While consistent timing is generally recommended for maintaining steady levels in the body, the treatment instructions for a missed dose imply some flexibility. The instruction for a missed dose supports the idea that the treatment's effectiveness may not be compromised by minor variances in daily timing. Taking the medicine as consistently as possible is the advised approach.


Q: Is a metallic taste in the mouth a known side effect of Biomoxin?

A metallic taste is not specifically listed as a common or frequent adverse event in primary regulatory documents. However, some international patient information includes a loss of sense of taste (ageusia) or a distorted taste (dysgeusia) as a potential side effect.


Q: Does Biomoxin interact with common blood pressure medications?

Official drug interaction information notes that Doxycycline has known interactions with certain diuretics, which are a class of medication often used to help manage blood pressure. Due to the wide variety of blood pressure medicines, any potential for interaction depends on the specific drug a person is using.


Q: How certain is the evidence supporting the use of Biomoxin?

In many official public health guidelines, the evidence supporting the use of Biomoxin for certain indications is often classified using methods like GRADE (Grading of Recommendations Assessment, Development and Evaluation). This can result in classifications such as 'moderate' certainty of evidence, which means the available data provides a reasonable basis for making recommendations.


Q: What happens if I take Biomoxin for longer than intended?

According to official regulatory warnings, taking Biomoxin (Doxycycline) for a prolonged duration may lead to an increased risk of serious adverse effects. These effects include potential permanent tooth discoloration in younger children and possible alterations to bone growth rate. Adherence to the prescribed treatment duration is a key part of following official guidelines.


Q: Can Biomoxin cause changes in mood or anxiety?

Mood or anxiety changes are not listed among the commonly reported side effects in regulatory documents. However, in rare instances, a serious side effect called Benign Intracranial Hypertension has been documented, which can involve certain neurological symptoms.


Q: Can Biomoxin be crushed or split for easier use?

Official preparation guidelines for Doxycycline note that, in specific circumstances, the tablets can be crushed and mixed with water or food to aid administration. This method is mentioned in specific guidelines to facilitate administration when whole tablets cannot be swallowed.


Q: Are there any common reasons Biomoxin might not be effective for someone?

Official labeling indicates that Biomoxin may be less effective if its absorption is impaired during intake. This impairment is documented to occur when the medicine is taken at the same time as certain products containing substances like calcium, iron, or magnesium, which bind to the drug. Also, some co-administered drugs can speed up the rate at which the body clears the medicine.


Q: How quickly does Biomoxin leave the body?

The time it takes for Biomoxin to leave the body is measured by its half-life—the time required for the drug concentration to decrease by half. While the exact numerical half-life is not typically listed for patients, regulatory documents mention certain drugs that can significantly decrease this half-life, meaning they cause Biomoxin to leave the body faster than usual.


Q: How does Biomoxin compare to older treatments for the same condition?

Studies have been conducted to evaluate whether using Biomoxin (Doxycycline) in combination with an established therapy is associated with a different outcome profile when compared to older treatment methods. This research aims to explore the results when Biomoxin is used alongside established therapies.

How should Biomoxin be stored and disposed of?

How to Store and Dispose of Biomoxin (Doxycycline)

Official regulatory guidelines dictate specific storage and disposal requirements for Doxycycline (Biomoxin) to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection Protect from light, excess heat, and moisture; keep the container tightly closed.
Child Safety Keep the medicine out of the sight and reach of children.
Reconstituted Liquid Discard the oral suspension after 14 days from the time of mixing.

Disposal Instructions

Unused or expired medicine must be disposed of according to local pharmaceutical waste protocols. The preferred method is using an authorized drug take-back program. If this is unavailable, the medicine may be prepared for household trash by mixing with an unappealing substance and sealing it in a separate container, following general regulatory disposal steps.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biomoxin found in:

A-Z Index: